1,703 Results
Novo Nordisk's ziltivekimab fails to significantly reduce cardiovascular risk in a Phase III trial, sending shares down 7.3%.
Simantini Singh Deo | Aug 03, 2026
Ascentage Pharma names Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO to drive its global business development and commercial expansion.
Simantini Singh Deo | Aug 03, 2026
Novartis wins FDA approval for Pluvicto in earlier-stage metastatic hormone-sensitive prostate cancer, nearly doubling eligible patients.
Simantini Singh Deo | Aug 01, 2026
XORTX Therapeutics appoints Depesh Narotam, a 20-year financial services veteran, as an independent director to its Board.
Simantini Singh Deo | Aug 01, 2026
Rose Hill Life Sciences names Jama Pitman, a 25-year biopharma veteran, as CEO to lead its psilocybin-based clinical programs.
Simantini Singh Deo | Aug 01, 2026
Profusa signs an Option Agreement to acquire G3 Vision Labs, aiming to build a public diagnostics business on a $111 million revenue base.
Simantini Singh Deo | Aug 01, 2026
Vistagen appoints Dr. Douglas J. Williamson, veteran neuroscience drug developer, to its Board of Directors to support its pherine pipeline.
Simantini Singh Deo | Aug 01, 2026